FDA Warns Baxter On Hemophilia Drug Promotion
The U.S. Food and Drug Administration has warned Baxter Healthcare Corp. over a promotion of one of its hemophilia drugs that the agency says overstates the coagulant's safety and efficacy....To view the full article, register now.
Already a subscriber? Click here to view full article